NCT04601454

Brief Summary

Prospective, multi-center, open-label, post-market study to evaluate the efficacy and energy use of a low energy DTM™ (DTM-LE) SCS therapy for pain relief.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
57

participants targeted

Target at P25-P50 for not_applicable chronic-pain

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

13 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 5, 2020

Completed
18 days until next milestone

First Posted

Study publicly available on registry

October 23, 2020

Completed
13 days until next milestone

Study Start

First participant enrolled

November 5, 2020

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 29, 2021

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 25, 2022

Completed
6 months until next milestone

Results Posted

Study results publicly available

February 24, 2023

Completed
Last Updated

February 24, 2023

Status Verified

February 1, 2023

Enrollment Period

1.1 years

First QC Date

October 5, 2020

Results QC Date

November 22, 2022

Last Update Submit

February 21, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Visual Analog Scale (VAS)

    To characterize changes in overall (back and leg) pain intensity. Pain will be assessed using a VAS (0-10 cm) with 0 cm meaning "no pain" and 10 cm meaning "worst pain imaginable". Overall pain is defined as a combination of back and leg pain, but not pain from other body parts. Subjects will be asked to report their average pain intensity that is related to their SCS device treatment "in the last 24 hours" by marking a line perpendicular to the VAS line at the point that represents their pain intensity.

    Baseline to 3 Months

Secondary Outcomes (4)

  • Programming Parameters: Frequency in Hertz (Hz)

    12 Month

  • Programming Parameters: Pulse Width in Microseconds (µs)

    12 Month

  • Programming Parameters: Amplitude (Intensity) in Milliamp (mA)

    12 Month

  • Programming Parameters: Impedance Range in Ohms

    12 Month

Study Arms (1)

Spinal Cord Stimulation

EXPERIMENTAL

Enrolled subjects are implanted with a rechargeable spinal cord stimulation system that is activated and programmed to on-label parameters.

Device: Spinal Cord Stimulation System

Interventions

Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.

Also known as: Medtronic Intellis AdaptiveStim Neurostimulation System
Spinal Cord Stimulation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Willing and able to provide signed and dated informed consent
  • Capable of comprehending and consenting in English
  • Candidate per labeling for an SCS system as an aid in the management of chronic, intractable pain of the trunk and/or limbs
  • Has moderate to severe back and leg pain
  • Stable pain medications for back and leg pain for at least 28 days prior to enrollment
  • Willing and able to comply with all study procedures and visits
  • Willing and able to not increase their pain medications through the 3-Month visit
  • Able to differentiate between pain associated with the indication for SCS implant and other types of pain

You may not qualify if:

  • Previously trialed or implanted with a stimulator or intrathecal drug delivery system
  • Expected to be inaccessible for follow-up
  • Current diagnosis of moderate to severe central lumbar spinal stenosis with symptomatic neurogenic claudication
  • Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results
  • If female, is pregnant or is of child-bearing potential and unwilling to use a medically acceptable form of birth control during the study
  • Has untreated major psychiatric comorbidity
  • Serious drug-related behavioral issues
  • Unable to achieve supine or prone position
  • Classified as vulnerable or requires a legally authorized representative (LAR)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

IPM Medical Group

Walnut Creek, California, 94598, United States

Location

Goodman Campbell Brain and Spine

Carmel, Indiana, 46032, United States

Location

Drez One LLC

Somerset, Kentucky, 42503, United States

Location

Carolinas Pain Center

Huntersville, North Carolina, 28078, United States

Location

Novant Health

Winston-Salem, North Carolina, 27103, United States

Location

Oklahoma Pain Physicians

Oklahoma City, Oklahoma, 73120, United States

Location

Center for Interventional Pain and Spine

Lancaster, Pennsylvania, 17604, United States

Location

Pain Diagnostics and Interventional Care

Sewickley, Pennsylvania, 15143, United States

Location

Delaware Valley Pain and Spine Institute

Trevose, Pennsylvania, 19053, United States

Location

The Woodlands Pain Institute

Conroe, Texas, 77384, United States

Location

The Burkhart Research Institute for Orthopaedics

San Antonio, Texas, 78216, United States

Location

Sprintz Center for Pain

Shenandoah, Texas, 77384, United States

Location

Precision Spine Care

Tyler, Texas, 75701, United States

Location

MeSH Terms

Conditions

Chronic Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
DTM-LE Clinical Research Study Team
Organization
Medtronic

Study Officials

  • Restorative Therapies Group Restorative Therapies Group

    Medtronic

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 5, 2020

First Posted

October 23, 2020

Study Start

November 5, 2020

Primary Completion

November 29, 2021

Study Completion

August 25, 2022

Last Updated

February 24, 2023

Results First Posted

February 24, 2023

Record last verified: 2023-02

Locations